Macara Jacobs, PA
Medical · Saint Louis, MONPI 1053466763
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,894 of the $3,870 with a category attached, or 74.8%. 28 manufacturers reported payments, led by Axonics, Inc. at 41.9% of the total. Reporting peaked in 2022 at $1,975 and has fallen 71.0% since, to $573 in 2025.
Across 131 payments — averaging $29.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- AbbVie$532
- Astellas Pharma US Inc$377
- Medtronic$243
- Coloplast$210
- Boston Scientific$113
- plus $774 from 22 others
Across 1 payment — averaging $280.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$280
What the payments were for
- Travel & lodging$81621%
- Food & beverage$2,89475%
- Education$1604%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 25 | $1,621 |
| AbbVie | 33 | $532 |
| Astellas Pharma US Inc | 18 | $377 |
| Medtronic | 3 | $243 |
| Coloplast | 7 | $210 |
| Boston Scientific | 1 | $113 |
| Procept Biorobotics Corporation | 3 | $93 |
| Sumitomo Pharma America, Inc. | 4 | $81 |
| Bayer | 5 | $78 |
| Agile Therapeutics, Inc. | 5 | $70 |
| Mayne Pharma Commercial LLC | 4 | $66 |
| Amgen | 3 | $45 |
| Evofem Biosciences, Inc. | 3 | $40 |
| Mylan Pharmaceuticals Inc. | 2 | $34 |
| Pfizer | 2 | $30 |
| Urogen Pharma, Inc. | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Vertex | 1 | $21 |
| Millicent US Inc | 1 | $19 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
| Myovant Sciences Inc. | 1 | $18 |
| Photocure Inc | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Baudax Bio Inc. | 1 | $16 |
| Sage Therapeutics, LLC | 1 | $16 |
| Antares Pharma, Inc. | 1 | $14 |
| Valencia Technologies Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$1,054
- INTERSTIM$222
- Axonics r-SNM System$127
- ALTIS$101
How this compares
$3,870 in reported general payments places this provider in the 80th percentile of 198 medical providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 222 | $193,512 |
| GemtesaVibegron | 64 | $49,766 |
| ElmironPentosan Polysulfate Sodium | 16 | $9,713 |
| Solifenacin Succinate | 149 | $9,689 |
| Oxybutynin Chloride ErOxybutynin Chloride | 189 | $4,432 |
| Estradiol | 66 | $3,794 |
| Tolterodine Tartrate ErTolterodine Tartrate | 19 | $2,276 |
| Methenamine Hippurate | 18 | $1,610 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 81 | $1,515 |
| Trospium Chloride | 12 | $1,318 |
| Bethanechol Chloride | 23 | $1,273 |
| Cephalexin | 25 | $317 |
| Baclofen | 23 | $273 |
| Ciprofloxacin Hcl | 16 | $142 |
| Amitriptyline Hcl | 14 | $137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $377 | $193,512222 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $81 | $49,76664 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 198 medical providers in Missouri.
Other medical in Saint Louis
- Amy MosmanSaint Louis$21K
- Alexa Fider-WhyteSaint Louis$18K
- Megan Isaacson-SchmidSaint Louis$16K
- Erin YoffieSaint Louis$16K
- Beatrice BernhartSaint Louis$15K
- Lindsay ExlineSaint Louis$8K
- Mustafa AhmedSaint Louis$8K
- Elizabeth HowardSaint Louis$4K
- Kayla BergmannSaint Louis$4K
- David VanhoornbeekSaint Louis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.